Investigating cell death responses associated with histotripsy ablation of canine osteosarcoma

References

• Rowell JL, McCarthy DO, Alvarez CE. Dog models of naturally occurring cancer. Trends Mol Med. 2011;17(7):380–388. doi: 10.1016/j.molmed.2011.02.004.
   PubMed Web of Science ®Google Scholar
• Luu AK, Wood GA, Viloria-Petit AM. Recent advances in the discovery of biomarkers for canine osteosarcoma. Front Vet Sci. 2021;8:734965. doi: 10.3389/fvets.2021.734965.
   PubMed Web of Science ®Google Scholar
• Mason NJ. Comparative immunology and immunotherapy of canine osteosarcoma. Adv Exp Med Biol. 2020;1258:199–221. doi: 10.1007/978-3-030-43085-6_14.
   PubMed Web of Science ®Google Scholar
• Mason NJ, Gnanandarajah JS, Engiles JB, et al. Immunotherapy with a HER2-Targeting listeria induces HER2-Specific immunity and demonstrates potential therapeutic effects in a phase I trial in canine osteosarcoma. Clin Cancer Res. 2016;22(17):4380–4390. doi: 10.1158/1078-0432.CCR-16-0088.
   PubMed Web of Science ®Google Scholar
• Poon AC, Matsuyama A, Mutsaers AJ. Recent and current clinical trials in canine appendicular osteosarcoma. Can Vet J. 2020;61(3):301–308.
   PubMed Web of Science ®Google Scholar
• Wycislo KL, Fan TM. The immunotherapy of canine osteosarcoma: a historical and systematic review. J Vet Intern Med. 2015;29(3):759–769. doi: 10.1111/jvim.12603.
   PubMed Web of Science ®Google Scholar
• Frimberger AE, Chan CM, Moore AS. Canine osteosarcoma treated by Post-Amputation sequential accelerated doxorubicin and carboplatin chemotherapy: 38 cases. J Am Anim Hosp Assoc. 2016;52(3):149–156. doi: 10.5326/JAAHA-MS-6315.
   PubMed Web of Science ®Google Scholar
• Friebele JC, Peck J, Pan X, et al. Osteosarcoma: a meta-analysis and review of the literature. Am J Orthop (Belle Mead NJ). 2015;44(12):547–553.
   PubMedGoogle Scholar
• Meazza C, Scanagatta P. Metastatic osteosarcoma: a challenging multidisciplinary treatment. Expert Rev Anticancer Ther. 2016;16(5):543–556. doi: 10.1586/14737140.2016.1168697.
   PubMed Web of Science ®Google Scholar
• Schiffman JD, Breen M. Comparative oncology: what dogs and other species can teach us about humans with cancer. Philos Trans R Soc Lond B Biol Sci. 2015;370(1673):20140231. doi: 10.1098/rstb.2014.0231.
   PubMed Web of Science ®Google Scholar
• Arnold L, Hendricks-Wenger A, Coutermarsh-Ott S, et al. Histotripsy ablation of bone tumors: feasibility study in excised canine osteosarcoma tumors. Ultrasound Med Biol. 2022;48(7):1356. doi: 10.1016/j.ultrasmedbio.2022.03.012.
   PubMed Web of Science ®Google Scholar
• Ruger LN, Hay AN, Gannon JM, et al. Histotripsy ablation of spontaneously occurring canine bone tumors. IEEE Trans Biomed Eng. 2023;70(1):331–342. doi: 10.1109/TBME.2022.3191069.
   PubMed Web of Science ®Google Scholar
• Ruger LN, Hay AN, Vickers ER, et al. Characterizing the ablative effects of histotripsy for osteosarcoma: in vivo study in dogs. Cancers (Basel). 2023;15(3):15. doi: 10.3390/cancers15030741.
   Web of Science ®Google Scholar
• Bader KB, Vlaisavljevich E, Maxwell AD. For whom the bubble grows: physical principles of bubble nucleation and dynamics in histotripsy ultrasound therapy. Ultrasound Med Biol. 2019;45(5):1056–1080. doi: 10.1016/j.ultrasmedbio.2018.10.035.
   PubMed Web of Science ®Google Scholar
• Vlaisavljevich E, Maxwell A, Mancia L, et al. Visualizing the histotripsy process: bubble cloud-cancer cell interactions in a tissue-mimicking environment. Ultrasound Med Biol. 2016;42(10):2466–2477. doi: 10.1016/j.ultrasmedbio.2016.05.018.
   PubMed Web of Science ®Google Scholar
• Khokhlova VA, Fowlkes JB, Roberts WW, et al. Histotripsy methods in mechanical disintegration of tissue: towards clinical applications. Int J Hyperthermia. 2015;31(2):145–162. doi: 10.3109/02656736.2015.1007538.
   PubMed Web of Science ®Google Scholar
• Schade GR, Keller J, Ives K, et al. Histotripsy focal ablation of implanted prostate tumor in an ACE-1 canine cancer model. J Urol. 2012;188(5):1957–1964. doi: 10.1016/j.juro.2012.07.006.
   PubMed Web of Science ®Google Scholar
• Hay AL, Gannon J, Sheppard H, Investigating histotripsy as a novel treatment for canine osteosarcoma., et al. Veterinary and comparative oncology 2021; Conference Proceedings.
   Google Scholar
• Latifi M, Hay A, Carroll J, et al. Focused ultrasound tumour ablation in small animal oncology. Vet Comp Oncol. 2021;19(3):411–419. doi: 10.1111/vco.12742.
   PubMed Web of Science ®Google Scholar
• Hendricks-Wenger A, Arnold L, Gannon J, et al. Histotripsy ablation in preclinical animal models of cancer and spontaneous tumors in veterinary patients: a review. IEEE Trans Ultrason Ferroelectr Freq Control. 2022;69(1):5–26. doi: 10.1109/TUFFC.2021.3110083.
   PubMed Web of Science ®Google Scholar
• Wah TM, Pech M, Thormann M, et al. A multi-centre, single arm, non-randomized, prospective European trial to evaluate the safety and efficacy of the HistoSonics system in the treatment of primary and metastatic liver cancers (#HOPE4LIVER). Cardiovasc Intervent Radiol. 2023;46(2):259–267. doi: 10.1007/s00270-022-03309-6.
   Google Scholar
• Xu Z, Hall TL, Vlaisavljevich E, et al. Histotripsy: the first noninvasive, non-ionizing, non-thermal ablation technique based on ultrasound. Int J Hyperthermia. 2021;38(1):561–575. doi: 10.1080/02656736.2021.1905189.
   PubMed Web of Science ®Google Scholar
• Schuster TG, Wei JT, Hendlin K, et al. Histotripsy treatment of benign prostatic enlargement using the vortx R(x) system: initial human safety and efficacy outcomes. Urology. 2018;114:184–187. doi: 10.1016/j.urology.2017.12.033.
   PubMed Web of Science ®Google Scholar
• Messas E, A IJ, Goudot G, et al. Feasibility and performance of noninvasive ultrasound therapy in patients with severe symptomatic aortic valve stenosis: a first-in-Human study. Circulation. 2021;143(9):968–970. doi: 10.1161/CIRCULATIONAHA.120.050672.
   PubMed Web of Science ®Google Scholar
• Elfatairy K. First-in-human histotripsy trial for liver tumor treatment: the new echo superpower. Radiol Imaging Cancer. 2023;5(1):e229026.
   PubMedGoogle Scholar
• Hendricks-Wenger A, Hutchison R, Vlaisavljevich E, et al. Immunological effects of histotripsy for cancer therapy. Front Oncol. 2021;11:681629. doi: 10.3389/fonc.2021.681629.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, et al. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31(1):51–72. doi: 10.1146/annurev-immunol-032712-100008.
   PubMed Web of Science ®Google Scholar
• Ahmed A, Tait SWG. Targeting immunogenic cell death in cancer. Mol Oncol. 2020;14(12):2994–3006. doi: 10.1002/1878-0261.12851.
   PubMed Web of Science ®Google Scholar
• Gupta G, Borglum K, Chen H. Immunogenic cell death: a step ahead of autophagy in cancer therapy. J Cancer Immunol (Wilmington). 2021;3(1):47–59.
   PubMedGoogle Scholar
• Pahk KJ, Shin CH, Bae IY, et al. Boiling histotripsy-induced partial mechanical ablation modulates tumour microenvironment by promoting immunogenic cell death of cancers. Sci Rep. 2019;9(1):9050. doi: 10.1038/s41598-019-45542-z.
   PubMed Web of Science ®Google Scholar
• Candeias SM, Gaipl US. The immune system in cancer prevention, development and therapy. Anticancer Agents Med Chem. 2016;16(1):101–107.
   PubMed Web of Science ®Google Scholar
• Pepple AL, Guy JL, McGinnis R, et al. Spatiotemporal local and abscopal cell death and immune responses to histotripsy focused ultrasound tumor ablation. Front Immunol. 2023;14:1012799. doi: 10.3389/fimmu.2023.1012799.
   PubMed Web of Science ®Google Scholar
• Qu S, Worlikar T, Felsted AE, et al. Non-thermal histotripsy tumor ablation promotes abscopal immune responses that enhance cancer immunotherapy. J Immunother Cancer. 2020;8(1):e000200. doi: 10.1136/jitc-2019-000200.
   PubMed Web of Science ®Google Scholar
• Hendricks-Wenger A, Sereno J, Gannon J, et al. Histotripsy ablation alters the tumor microenvironment and promotes immune system activation in a subcutaneous model of pancreatic cancer. IEEE Trans Ultrason Ferroelectr Freq Control. 2021;68(9):2987–3000. doi: 10.1109/TUFFC.2021.3078094.
   PubMed Web of Science ®Google Scholar
• Banks HT, Sutton KL, Thompson WC, et al. Estimation of cell proliferation dynamics using CFSE data. Bull Math Biol. 2011;73(1):116–150. doi: 10.1007/s11538-010-9524-5.
   PubMed Web of Science ®Google Scholar
• Kolberg L, Raudvere U, Kuzmin I, et al. gprofiler2 – an R package for gene list functional enrichment analysis and namespace conversion toolset g: profiler. F1000Res. 2020;9:709. doi: 10.12688/f1000research.24956.2.
   Google Scholar
• Raudvere U, Kolberg L, Kuzmin I, et al. g: profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 2019;47(W1):W191–W198. w8. doi: 10.1093/nar/gkz369.
   PubMed Web of Science ®Google Scholar
• Legare ME, Bush J, Ashley AK, et al. Cellular and phenotypic characterization of canine osteosarcoma cell lines. J Cancer. 2011;2:262–270. doi: 10.7150/jca.2.262.
   PubMed Web of Science ®Google Scholar
• Scott MC, Tomiyasu H, Garbe JR, et al. Heterotypic mouse models of canine osteosarcoma recapitulate tumor heterogeneity and biological behavior. Dis Model Mech. 2016;9(12):1435–1444.
   PubMed Web of Science ®Google Scholar
• Wilson-Robles H, Franks K, Pool R, et al. Characterization of five newly derived canine osteosarcoma cell lines. BMC Vet Res. 2019;15(1):357. doi: 10.1186/s12917-019-2099-y.
   PubMed Web of Science ®Google Scholar
• Sánchez-Céspedes R, Accornero P, Miretti S, et al. In vitro and in vivo effects of toceranib phosphate on canine osteosarcoma cell lines and xenograft orthotopic models. Vet Comp Oncol. 2020;18(1):117–127. doi: 10.1111/vco.12562.
   PubMed Web of Science ®Google Scholar
• Messmer MN, Snyder AG, Oberst A. Comparing the effects of different cell death programs in tumor progression and immunotherapy. Cell Death Differ. 2019;26(1):115–129. doi: 10.1038/s41418-018-0214-4.
   PubMed Web of Science ®Google Scholar
• Fan Y, Dutta J, Gupta N, et al. Regulation of programmed cell death by NF-kappaB and its role in tumorigenesis and therapy. Adv Exp Med Biol. 2008;615:223–250.
   PubMed Web of Science ®Google Scholar
• Giampazolias E, Zunino B, Dhayade S, et al. Mitochondrial permeabilization engages NF-κB-dependent anti-tumour activity under caspase deficiency. Nat Cell Biol. 2017;19(9):1116–1129. doi: 10.1038/ncb3596.
   PubMed Web of Science ®Google Scholar
• Yatim N, Jusforgues-Saklani H, Orozco S, et al. RIPK1 and NF-κB signaling in dying cells determines cross-priming of CD8+ T cells. Science. 2015;350(6258):328–334. doi: 10.1126/science.aad0395.
   PubMed Web of Science ®Google Scholar
• Wang S, Zhang Y. HMGB1 in inflammation and cancer. J Hematol Oncol. 2020;13(1):116. doi: 10.1186/s13045-020-00950-x.
   PubMed Web of Science ®Google Scholar
• Zhu X, Messer JS, Wang Y, et al. Cytosolic HMGB1 controls the cellular autophagy/apoptosis checkpoint during inflammation. J Clin Invest. 2015;125(3):1098–1110. doi: 10.1172/JCI76344.
   PubMed Web of Science ®Google Scholar
• Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418(6894):191–195. doi: 10.1038/nature00858.
   PubMed Web of Science ®Google Scholar
• Worlikar T, Mendiratta-Lala M, Vlaisavljevich E, et al. Effects of histotripsy on local tumor progression in an in vivo orthotopic rodent liver tumor model. BME Front. 2020;2020. doi: 10.34133/2020/9830304.
   PubMedGoogle Scholar